Thorsten Hornemann

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Cloning and initial characterization of a new subunit for mammalian serine-palmitoyltransferase
    Thorsten Hornemann
    Institute for Clinical Chemistry, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    J Biol Chem 281:37275-81. 2006
  2. ncbi Sphingolipids and atherosclerosis
    Thorsten Hornemann
    Inst for Clinical Chemistry, University Hospital Zuerich, Raemistrasse 100, 8091 Zuerich, Switzerland
    Atherosclerosis 226:16-28. 2013
  3. ncbi Is the mammalian serine palmitoyltransferase a high-molecular-mass complex?
    Thorsten Hornemann
    Institute for Clinical Chemistry, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Biochem J 405:157-64. 2007
  4. ncbi A systematic comparison of all mutations in hereditary sensory neuropathy type I (HSAN I) reveals that the G387A mutation is not disease associated
    Thorsten Hornemann
    Department for Clinical Chemistry, University Hospital Zurich, Raemistrasse 100, 8051, Zurich, Switzerland
    Neurogenetics 10:135-43. 2009
  5. ncbi The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases
    Thorsten Hornemann
    Institute for Clinical Chemistry, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Biol Chem 284:26322-30. 2009
  6. ncbi Deoxysphingoid bases as plasma markers in diabetes mellitus
    Mariana Bertea
    Institute for Clinical Chemistry, University Hospital Zurich and Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
    Lipids Health Dis 9:84. 2010
  7. ncbi An improved method to determine serine palmitoyltransferase activity
    Markus F Rütti
    Institute for Clinical Chemistry, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Lipid Res 50:1237-44. 2009
  8. ncbi Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids
    Anke Penno
    Institute for Clinical Chemistry, University Hospital Zurich, Raemistrasse 100, CH 8091 Zurich, Switzerland
    J Biol Chem 285:11178-87. 2010
  9. ncbi SPTLC1 binds ABCA1 to negatively regulate trafficking and cholesterol efflux activity of the transporter
    Norimasa Tamehiro
    Lipid Metabolism Unit and Center for Computational and Integrative Biology, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, Massachusetts 02114, USA
    Biochemistry 47:6138-47. 2008

Collaborators

Detail Information

Publications9

  1. ncbi Cloning and initial characterization of a new subunit for mammalian serine-palmitoyltransferase
    Thorsten Hornemann
    Institute for Clinical Chemistry, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    J Biol Chem 281:37275-81. 2006
    ..The expression of two SPT isoforms could be a cellular mechanism to adjust SPT activity to tissue-specific requirements of sphingolipid synthesis...
  2. ncbi Sphingolipids and atherosclerosis
    Thorsten Hornemann
    Inst for Clinical Chemistry, University Hospital Zuerich, Raemistrasse 100, 8091 Zuerich, Switzerland
    Atherosclerosis 226:16-28. 2013
    ..Here we discuss recent mechanistic insights obtained in animal and epidemiological studies that have greatly enhanced our understanding of mechanisms how sphingolipids affect the atherosclerotic process...
  3. ncbi Is the mammalian serine palmitoyltransferase a high-molecular-mass complex?
    Thorsten Hornemann
    Institute for Clinical Chemistry, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Biochem J 405:157-64. 2007
    ..The observed dynamic composition of the SPT complex could provide a cellular mechanism to adjust SPT activity to tissue specific requirements in sphingolipid synthesis...
  4. ncbi A systematic comparison of all mutations in hereditary sensory neuropathy type I (HSAN I) reveals that the G387A mutation is not disease associated
    Thorsten Hornemann
    Department for Clinical Chemistry, University Hospital Zurich, Raemistrasse 100, 8051, Zurich, Switzerland
    Neurogenetics 10:135-43. 2009
    ..These findings were genetically confirmed by the identification of a nuclear HSAN family which showed segregation of the G387A variant as a non-synonymous SNP...
  5. ncbi The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases
    Thorsten Hornemann
    Institute for Clinical Chemistry, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Biol Chem 284:26322-30. 2009
    ..In conclusion, we show that the SPTLC3 subunit generates C(16)-sphingoid bases and that sphingolipids with a C(16) backbone constitute a significant proportion of human plasma sphingolipids...
  6. ncbi Deoxysphingoid bases as plasma markers in diabetes mellitus
    Mariana Bertea
    Institute for Clinical Chemistry, University Hospital Zurich and Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
    Lipids Health Dis 9:84. 2010
    ....
  7. ncbi An improved method to determine serine palmitoyltransferase activity
    Markus F Rütti
    Institute for Clinical Chemistry, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Lipid Res 50:1237-44. 2009
    ..The suggested HPLC method offers several advantages, most importantly, a 20-fold lower detection limit compared with the radioactive assay and the possibility to use an internal standard to correct for variation in the extraction...
  8. ncbi Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids
    Anke Penno
    Institute for Clinical Chemistry, University Hospital Zurich, Raemistrasse 100, CH 8091 Zurich, Switzerland
    J Biol Chem 285:11178-87. 2010
    ..Based on these observations, we conclude that HSAN1 is caused by a gain of function mutation, which results in the formation of two atypical and neurotoxic sphingolipid metabolites...
  9. ncbi SPTLC1 binds ABCA1 to negatively regulate trafficking and cholesterol efflux activity of the transporter
    Norimasa Tamehiro
    Lipid Metabolism Unit and Center for Computational and Integrative Biology, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, Massachusetts 02114, USA
    Biochemistry 47:6138-47. 2008
    ..In composite, these results indicate that the physical interaction of ABCA1 and SPTLC1 results in reduction of ABCA1 activity and that inhibition of this interaction produces enhanced cholesterol efflux...